Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 2/20 | 0.33 |
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
| ▸ | TNF | P01375 | 1/20 | 0.33 |
| ▸ | IL1B | P01584 | 1/20 | 0.33 |
| ▸ | IKZF1 | Q13422 | 1/20 | 0.33 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.33 |
| ▸ | IKZF3 | Q9UKT9 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30001714 | 0.78 | CRBN (0.44) | CRBNBRD4TNFIL1BIKZF1 | |
| SCHEMBL476941 | 0.78 | CRBN (0.44) | CRBNBRD4TNFIL1BIKZF1 | |
| SCHEMBL28769332 | 0.75 | MEN1 (0.34) | CRBNBRD4TNFIL1BIKZF1 | |
| SCHEMBL3739793 | 0.73 | DDB1 (0.43) | CRBNBRD4TNFIL1BIKZF1 | |
| SCHEMBL6542438 | 0.71 | DDB1 (0.32) | CRBNDDB1 | |
| SCHEMBL3996435 | 0.70 | CRBN (0.42) | CRBNBRD4TNFIL1BIKZF1 | |
| SCHEMBL3756597 | 0.66 | CRBN (0.44) | CRBNBRD4TNFIL1BIKZF1 | |
| SCHEMBL3755200 | 0.66 | HTR2A (0.36) | CRBNBRD4TNFIL1BIKZF1 | |
| SCHEMBL3744126 | 0.65 | DDB1 (0.44) | CRBNDDB1 | |
| SCHEMBL6541877 | 0.65 | CARM1 (0.42) | CRBNBRD4DDB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3077547-A2 | METHODS FOR TREATING HEMATOLOGICAL CANCERS AND THE USE OF BIOMARKERS AS A PREDICTOR OF CLINICAL SENSITIVITY TO IMMUNODULATORY THERAPIES | Celgene Corporation (US) | 2016-10-12 | — | — | EP | disclosed |
| WO-2015085160-A2 | METHODS FOR TREATING HEMATOLOGICAL CANCERS AND THE USE OF BIOMARKERS AS A PREDICTOR OF CLINICAL SENSITIVITY TO IMMUNODULATORY THERAPIES | CELGENE CORPORATION (US) | 2015-06-11 | — | — | WO | disclosed |
| EP-2111231-A2 | METHODS AND COMPOSITIONS FOR IMPROVING IMMUNE RESPONSES | NorthEastern University (US) | 2009-10-28 | — | — | EP | disclosed |
| WO-2008147482-A2 | METHODS AND COMPOSITIONS FOR IMPROVING IMMUNE RESPONSES | NORTHEASTERN UNIVERSITY (US) | 2008-12-04 | — | — | WO | disclosed |